Neurizon appoints Dr Chris Bremer as CEO ahead of pivotal ALS trial readout
Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) has appointed Dr Chris Bremer (MD, PhD, MBA) as Chief Executive Officer, effective 1 October 2026. The CEO appointment strengthens the biotechnology company’s leadership as it advances its lead investigational therapy, NUZ-001, through late-stage clinical development.
The timing is notable. Bremer arrives as Neurizon advances NUZ-001 through Regimen I of the registrational Phase 2/3 HEALEY ALS Platform Trial, with topline results expected in late Q2 CY2027.
His appointment follows a comprehensive international executive search conducted by the Board with Coulter Partners. Bremer will be based in Melbourne and will initially serve as Chief Executive Officer without appointment to the Company’s Board.
He brings over 20 years of international pharmaceutical and biotechnology leadership experience spanning drug development, portfolio strategy, commercialisation and business development. During his career, Bremer has executed on over US$1Bn in licensing transactions.
When big ASX news breaks, our subscribers know first
A global pharma leader with US$1Bn in licensing deals behind him
Bremer spent approximately 20 years with Grünenthal, progressing through a series of increasingly senior commercial, strategic and global leadership roles across Europe, Latin America and other international markets.
As Executive Vice President, Early Products & Commercial Opportunities, he led portfolio strategy across preclinical and clinical development and lifecycle management, and co-chaired the company’s integrated R&D–Commercial governance board. He subsequently served as Grünenthal’s Interim Chief Commercial Officer, reporting to the company’s CEO.
His work spanned drug development, portfolio strategy, commercialisation and business development, including the evaluation and execution of in-licensing, out-licensing and strategic partnership transactions.
Following his tenure at Grünenthal, Bremer took on senior roles in entrepreneurial biotechnology. He served as Chief Development Officer of Navigo Proteins, working on development strategy for precision oncology and radiotheranostics programs. He was also the Founding Chief Executive Officer of GAIASO Theranostics, an Australian biotechnology company focused on radiopharmaceutical approaches in women’s health, before transitioning to the role of Chief Business Officer.
Key credentials and career highlights include:
-
Medical and doctoral qualifications, plus an MBA from INSEAD
-
Approximately 20 years at Grünenthal across Europe, Latin America and international markets
-
Led organisations of up to 500 employees across geographically distributed and cross-functional teams
-
Executed over US$1Bn in licensing transactions
Before his career in medicine and pharmaceuticals, Bremer represented Germany as an elite swimmer at the 1992 Olympic Games, subsequently captaining the German National Swimming Team at the 1996 Olympic Games.
His combination of scientific, medical, commercial and transactional experience signals the Board is positioning for the potential regulatory, development and strategic pathways that may follow the trial, not clinical execution alone.
What the HEALEY ALS Platform Trial means for Neurizon investors
Amyotrophic Lateral Sclerosis (ALS) is the most common form of Motor Neurone Disease (MND), a progressive neurodegenerative condition. NUZ-001 is Neurizon’s lead investigational therapy being developed for its treatment.
NUZ-001 targets TDP-43 aggregation, a protein misfolding pathway present in approximately 97% of ALS cases, distinguishing it mechanistically from approved therapies that address downstream symptoms rather than the core driver of motor neuron degeneration.
The HEALEY ALS Platform Trial is a registrational Phase 2/3 study. A platform trial evaluates multiple therapies under a shared framework, while “registrational” means the data is designed to support regulatory approval pathways if outcomes are positive.
NUZ-001 is being evaluated in 250 participants in Regimen I, with enrolment now complete. Topline results are expected in late Q2 CY2027.
Why does this matter to investors? A well-credentialed CEO appointment ahead of a pivotal binary readout carries weight because leadership continuity and commercial readiness shape how a company capitalises on a positive result. NUZ-001 remains an investigational product and is not approved for commercial use in any jurisdiction.
Board transition and the terms of Bremer’s appointment
Following Bremer’s commencement, Interim Executive Chairman Sergio Duchini transitions from Interim Executive Chair to Non-Executive Chair, working closely with Bremer during the leadership transition. Bremer will initially be appointed as Chief Executive Officer and will not be appointed as a Director of Neurizon Therapeutics Limited.
The principal terms of his appointment are set out below.
| Term | Arrangement |
|---|---|
| Position | Chief Executive Officer |
| Commencement | 1 October 2026 |
| Total Fixed Remuneration | A$450,000 per annum, inclusive of statutory superannuation |
| Short-Term Incentive | Target 30% of Total Fixed Remuneration, maximum 50%, subject to Board-approved performance objectives |
| Long-Term Incentive | Target equivalent to 100% of Total Fixed Remuneration, proposed to comprise 70% performance rights and 30% options, subject to performance conditions, Board approval and any required shareholder or regulatory approvals |
| Notice and termination | Either party may terminate without cause on 4 months’ written notice |
The incentive framework is intended to align Bremer’s remuneration with the creation of sustainable shareholder value. Performance measures are expected to include clinical and regulatory execution, capital management, strategic and business development outcomes, and leadership and governance performance.
Neurizon’s next phase: execution through to topline results
The Company has outlined a set of stated priorities for the period ahead:
-
Disciplined execution of the clinical program through to topline results
-
Continued regulatory and CMC readiness
-
Further development of the scientific evidence supporting NUZ-001
-
Preparation for potential development, partnering and commercial pathways, subject to the outcomes of the study
Commercial supply readiness is already underway, with Neurizon having executed a five-year GMP monepantel supply agreement with Elanco Animal Health, locking in the manufacturing foundation that any potential post-trial commercialisation or partnering pathway would depend on.
Bremer will be based in Melbourne and will work closely with Neurizon’s Australian and US teams. The Board believes his experience integrating scientific and clinical development with commercial strategy, portfolio management and strategic partnering is closely aligned with these priorities.
Dr Chris Bremer, incoming Chief Executive Officer
“My immediate priorities will be to support disciplined execution of the clinical and regulatory program, maintain a strong focus on capital and organisational readiness, and prepare thoughtfully for the potential strategic pathways that may follow topline results.”
Commenting on the selection, Interim Executive Chairman Sergio Duchini said Bremer “distinguished himself through his combination of medical and scientific credibility, commercial and business development experience and senior international leadership. Importantly, he understands how to connect scientific and clinical development with commercial strategy, strategic partnering and long-term value creation.”
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market on biotech and healthcare developments. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment news breaks.